AUTHORS
Angel Luis OROSCO-TTAMINA, MD, MBA, John Hall, MBBS2, Haider Al-Qayyim, MBBS3, Katalin Kelemen, MD PhD4, Jeanne Palmer, MD5, Aref Al-Kali, M.D.6, Candido E Rivera, MD7, Naseema Gangat, MBBS8, Animesh Pardanani, PhD, MBBS9, Ayalew Tefferi, MD10, Mazie Tsang, MD, MAS, MS11, Saurabh Chhabra, MD, MBBS12, Deepti H. Radia, MBBS, BSc, MRCPI, FRCPath, MSc Med Ed13, Cecilia Arana Yi, M.D.14
AFFILIATIONS
1 Mayo Clinic, Phoenix, Arizona, United States
2 Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom
3 Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom
4 Mayo Clinic, Phoenix, Arizona, United States
5 Mayo Clinic, Phoenix, Arizona, United States
6 Mayo Clinic, Rochester, Minnesota, United States
7 Mayo Clinic, Jacksonville, Florida, United States
8 Mayo Clinic, Rochester, Minnesota, United States
9 Mayo Clinic, Rochester, Minnesota, United States
10 Mayo Clinic, Rochester, Minnesota, United States
11 Mayo Clinic, Phoenix, Arizona, United States
12 Mayo Clinic, Phoenix, Arizona, United States
13 Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom
14 Mayo Clinic, Phoenix, Arizona, United States
ABSTRACT
Background: Systemic mastocytosis with an associated hematologic neoplasm (SM-AHN) most commonly involves myeloid neoplasms, whereas associated lymphoid neoplasms are uncommon and poorly characterized. Small retrospective studies, including our single-center cohort (Orosco-Ttamina et al., ASH 2025), suggest that SM with associated lymphoid neoplasms (SM-ALN) is a biologically distinct subgroup with predominantly indolent mast cell disease and favorable outcomes. However, the available evidence remains limited by small cohorts, particularly for plasma cell neoplasms. We performed an international multicenter study to characterize clinical and molecular features, treatment, and outcomes in SM-ALN.
Methods: We performed a retrospective multicenter study of patients with SM and an associated lymphoma, lymphoid leukemia, or plasma cell neoplasm treated across the Mayo Clinic Enterprise and Guy's and St Thomas' NHS Foundation Trust (London, UK) between 1984 and 2026. Patients with coexisting myeloid neoplasms at diagnosis and those with monoclonal gammopathy of undetermined significance were excluded. Variables included demographics, SM subtype, temporal sequence, histology, KIT D816V, additional mutations, treatment, response, and survival. Responses reflected treating-physician assessment among patients receiving disease-directed therapy with documented restaging. Owing to cohort size, analyses were descriptive.
Results: Thirty-one patients were included. The median age at SM diagnosis was 65 years (range, 38–84), and 16 (52%) were male. Twenty-eight patients (90%) had non-advanced SM (27 indolent and 1 smoldering), whereas three (10%) had aggressive SM. The associated lymphoid neoplasm preceded SM in 10 patients (32%), SM preceded the lymphoid neoplasm in 9 (29%), and the diagnoses were concurrent in 12 (39%). Histologies included chronic lymphocytic leukemia/small lymphocytic lymphoma (n=4), follicular lymphoma (n=3), diffuse large B-cell lymphoma (n=3), mantle cell lymphoma (n=2), Hodgkin lymphoma (n=2), marginal zone lymphoma (n=1), lymphoplasmacytic lymphoma/Waldenström macroglobulinemia (n=2), T-cell acute lymphoblastic leukemia (n=1), symptomatic multiple myeloma (n=6), smoldering multiple myeloma (n=4), and other mature B-cell neoplasms (n=3). KIT D816V was detected in 20 of 27 evaluable patients (74%). Additional mutations were identified in 9 patients (29%) and clustered in aggressive SM, with SRSF2/ASXL1/RUNX1-pathway genes accompanied by TP53, DNMT3A, IDH1, or JAK2, whereas non-advanced SM predominantly harbored isolated or lymphoid-lineage mutations that were not associated with SM progression or SM-related death. SM management consisted primarily of observation or symptom-directed therapy, with cytoreductive treatment reserved for selected patients with advanced or symptomatic disease. Treatment of the associated lymphoid neoplasm followed standard disease-specific approaches, including anti-CD20-based chemoimmunotherapy, ABVD, radiotherapy, targeted therapy, proteasome inhibitor-, immunomodulatory drug-, and anti-CD38-based regimens for plasma cell neoplasms. Responses were comparable to those expected for the underlying malignancy. Among patients with plasma cell neoplasms, no cases of extramedullary disease were identified. At a median follow-up of 7.6 years (range, 0.7–25.4) for lymphoid neoplasms and 36.5 months (range, 10–211) from myeloma diagnosis for plasma cell neoplasms, the median overall survival was not reached. Deaths were attributable to progressive lymphoid malignancy, treatment-related complications, or unrelated causes, whereas no patient with non-advanced SM died from mastocytosis.
Conclusions: SM associated with lymphoid neoplasms is characterized predominantly by non-advanced mastocytosis despite heterogeneous lymphoid histologies. Clinical management is driven by the associated lymphoid malignancy, whereas mastocytosis usually requires only observation or symptom-directed therapy. Adverse outcomes were largely confined to patients with aggressive SM harboring myeloid co-mutations, suggesting that mast cell disease stage and co-mutation profile, rather than lymphoid histology, identify patients at greatest risk. These findings support the use of standard disease-specific therapy for the associated lymphoid malignancy while individualizing mastocytosis-directed treatment according to SM subtype. Limitations include the small cohort size, limited molecular testing, and nonuniform restaging.
DISCLOSURES
Angel Luis OROSCO-TTAMINA, MD, MBA: Onviv, Inc. - Honoraria